A Prospective Clinical Investigation to Evaluate the Safety and Performance of 877PTY Toric IOL for Visual Correction of Corneal Astigmatism
Launched by MEDICONTUR MEDICAL ENGINEERING LTD · Aug 28, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients (18 years old and older);
- • cataract and/or corneal astigmatism diagnosis;
- • indication for cataract surgery or refractive lens exchange;
- • recommended cylinder correction with toric IOL with cylinder power ≥1.0D;
- • clear intraocular media other than cataract;
- • signed informed consent form;
- Exclusion Criteria:
- • irregular astigmatism;
- • patients who are not targeted to emmetropia (predicted residual spherical equivalent and/or astigmatism is out of the range of ±0.5D and ±0.38D respectively);
- • any retinopathy or maculopathy that affects the vision;
- • iris neovascularization;
- • congenital eye abnormality affecting visual performance;
- • advanced glaucoma;
- • pseudoexfoliation syndrome affecting IOL stability;
- • amblyopia;
- • uveitis;
- • retinal detachment;
- • prior ocular surgery in personal medical history;
- • irregular corneal curvature or corneal diseases affecting visual performance;
- • high myopia (axial length ≥ 26,5 mm);
- • inadequate visualization of the fundus on preoperative examination;
- • dilated pupil size not large enough to visualize toric IOL axis markings postoperatively based on the Investigator's decision;
- • eye trauma in medical history;
- • instability of keratometry or biometry measurements;
- • prior corneal refractive surgery such as LASIK, PRK, or SMILE;
- • patients deemed ineligible by the investigator because of any systemic disease or treatment;
- • pregnancy or lactation;
- • current use of systemic steroids or external ophthalmic drugs;
- • concurrent participation in another drug or device investigation.
- Intraoperative exclusions: the presence of the following intraoperative exclusion criteria will lead to the exclusion of the subject:
- • - Any unexpected or serious intraoperative complication that makes IOL implantation impossible or results in implantation of another type of IOL that is outside the scope of this clinical trial.
About Medicontur Medical Engineering Ltd
Medicontur Medical Engineering Ltd. is a leading innovator in the development of advanced medical devices, specializing in ophthalmic surgical solutions. With a commitment to enhancing patient outcomes through cutting-edge technology, the company focuses on the design and manufacturing of high-quality intraocular lenses and related surgical instruments. Driven by a passion for improving vision care, Medicontur leverages extensive research and clinical expertise to deliver products that meet the evolving needs of healthcare professionals and patients worldwide. Their rigorous clinical trial initiatives reflect their dedication to safety, efficacy, and regulatory compliance, ensuring that their innovations contribute positively to the field of ophthalmology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Győr, , Hungary
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported